Joseph H. Gardner
Net Worth
Last updated:
What is Joseph H. Gardner net worth?
The estimated net worth of Dr. Joseph H. Gardner is at least $7,015,842 as of 10 Jul 2019. He owns shares worth $996,642 as insider and has received compensation worth at least $6,019,200 in Aerpio Pharmaceuticals, Inc..
What is the salary of Joseph H. Gardner?
Dr. Joseph H. Gardner salary is $752,400 per year as Founder, Pres, Principal Executive Officer & Director in Aerpio Pharmaceuticals, Inc..
How old is Joseph H. Gardner?
Dr. Joseph H. Gardner is 69 years old, born in 1956.
What stocks does Joseph H. Gardner currently own?
As insider, Dr. Joseph H. Gardner owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aerpio Pharmaceuticals, Inc. (ARPO) | Founder, Pres, Principal Executive Officer & Director | 453,019 | $2.2 | $996,642 |
What does Aerpio Pharmaceuticals, Inc. do?
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
Joseph H. Gardner insider trading
Aerpio Pharmaceuticals key executives
Aerpio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Dhaval Desai Chief Strategy Officer
- Dr. Joseph H. Gardner (69) Founder, Pres, Principal Executive Officer & Director
- Ms. Regina Marek (56) Principal Financial Officer, Principal Accounting Officer & Vice President of Fin.